Latest Conference Articles

Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to hormone therapy.

In patients with advanced NSCLC, treatment with Jemperli plus chemotherapy showed promising effectiveness compared with Keytruda plus chemotherapy.

Expert answers to patients’ questions were offered as part of the CURE® Educated Patient® Prostate Cancer Summit.

An expert discussed how patients with breast cancer, particularly those with a BRCA mutation, should consider future fertility and breastfeeding when making treatment decisions.

An expert discussed how liquid and tissue biopsies can help monitor treatment and detect potential resistance in patients with non-small cell lung cancer.

Through regular follow-ups and symptom assessments, breast cancer survivors have the access to physical and emotional support they may need.

An expert explained the advantages and disadvantages of radiation as a treatment for patients with renal cell carcinoma, a type of kidney cancer.

It’s crucial for patients with prostate cancer to know that all treatments come with side effects, which may affect their quality of life.

An expert discussed the importance of patients learning about their specific type of breast cancer to understand potential treatment options.

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy for EGFR-mutated non-small cell lung cancer.

With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary incontinence and erectile dysfunction, an expert said.

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET imaging, an expert explained.

An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in treatment decision-making for many.

An expert discussed the importance of biomarkers in guiding treatment decisions for patients with metastatic breast cancer.

TULSA is a targeted prostate cancer treatment that uses ultrasound to destroy tumors while preserving healthy tissue.

An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.

Distance relapse-free survival was maintained in patients with pMMR locally advanced rectal cancer through non-operative management of the disease.

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

Benmelstobart plus anlotinib significantly improved survival versus Sutent in the first-line treatment of advanced renal cell carcinoma.

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.